France's ExonHit Therapeutics says it has identified a set of genes that may allow it to analyze blood samples to determine if a patient has Alzheimer's disease. In one study involving a group of 85 people, the firm said, the process was able to identify 78% of the people with Alzheimer's and 82% of those without it.

Full Story:

Related Summaries